Key Dates

Related Announcements

December 05, 2024 - NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required). See NOFO PAR-25-025.
December 05, 2024 - NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required). See NOFO PAR-25-026.

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this notice is to inform potential applicants of a change in the key dates for notices of funding opportunity (NOFO) PAR-25-025 "NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)" and PAR-25-026 "NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)". Specifically, 1 additional receipt date has been added for new applications and resubmission/revision applications. The NOFO will now expire on February 4, 2027.

The following sections of PAR-25-025 and PAR-25-026 have been updated in bold italics to reflect the additional receipt date and new expiration date. 

Part 1. Overview Information

Key Dates

The following table includes NIH standard due dates marked with an asterisk.

All applications are due by 5:00 PM local time of applicant organization. 

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Expiration Date

January 08, 2027

Due Dates for E.O. 12372

Not Applicable

Part 1. Overview Information

Key Dates

The following table includes NIH standard due dates marked with an asterisk.

All applications are due by 5:00 PM local time of applicant organization. 

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Expiration Date

February 04, 2027

Due Dates for E.O. 12372

Not Applicable

All other aspects of the NOFO remain the same.

Inquiries

Please direct all inquiries regarding this Notice to:

Scientific/Research Contact(s)

Division of Lung Diseases
National Heart, Lung, and Blood Institute (NHLBI)
Email: [email protected]
Subject: NOT-HL-27-002

Division of Blood Diseases and Resources
Clinical Trials
National Heart, Lung, and Blood Institute (NHLBI)
Email: [email protected]
Subject: NOT-HL-27-002

Division of Cardiovascular Sciences
National Heart, Lung, and Blood Institute (NHLBI)
Email: [email protected], [email protected]
Subject: NOT-HL-27-002

Financial/Grants Management Contact(s)

Office of Grants Management
National Heart, Lung, and Blood Institute (NHLBI)
Email: [email protected]
Subject: NOT-HL-27-002